bioSyntagma Information

Update (May 2023): bioSyntagma has pivoted and ceased active operations. This page is maintained for historical reference and to support accurate work history for former team members. bioSyntagma was a precision medicine company dedicated to transforming how cancer is treated by providing deep data on the uniqueness of each person’s cancer. The company’s Molecular Fingerprint™ (mPrint™) platform created a comprehensive, multi-omic and spatial profile of tissue to characterize tumors for companion diagnostic development and patient screening.

Website	http://www.biosyntagma.com
Revenue	$8 million
Employees	2 (0 on RocketReach)
Founded	2015
Phone	+1 623-266-6100
Technologies	JavaScript , HTML , PHP +14 more (view full list)
Industry	Biotechnology Research, Business Services General, Biotechnology, Social/Platform Software, Biomarker Discovery, Business Services, Science and Engineering, Other Devices and Supplies, Expression Analysis, Life Science, Data Visualization, Pharmaceutical Research, Artificial Intelligence, Spatial 'Omics
Keywords	Cancer Treatment, Precision Medicine, Molecular Diagnostics, Genomic Analysis, Multiomics, Oncology, Cancer Research, Personalized Medicine, Biomarker Discovery, Drug Development, Cancer Biomarkers, Next Generation Sequencing, Data Analytics, Clinical Trials, Cancer Genomics, Molecular Profiling, Proteomics, Transcriptomics, Liquid Biopsy
Competitors	Thermo Fisher Scientific, Agilent Technologies, Integrated DNA Technologies, GenScript, Twist Bioscience, BioRender, Synthego Corporation, BIOSYNEX, Codex DNA, ACTGene +30 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies
NAICS	NAICS Code 541713 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies